The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for relapsed or refractory
The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of
The European Commission (EC) has approved the marketing authorization for imetelstat (RYTELO), a first-in-class telomerase inhibitor, as a monotherapy for the treatment of
A study documenting peripheral T-cell lymphoma epidemiology across Latin America found a high prevalence of adult T-cell leukemia or lymphoma and extranodal natural
Ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models.
The combination of olutasidenib plus azacitidine produced “durable” responses in patients with relapsed or refractory mIDH1 acute myeloid leukemia (AML), according to a
In every phase of my career while I’ve been training, I have been lucky to be mentored by the major movers and shakers
Lintuzumab-Ac225 plus CLAG-M yielded “deep and meaningful responses” in patients with relapsed/refractory acute myeloid leukemia (AML), according the results of a phase 1
In this roundtable discussion on anemia management in MDS, the panel discusses the journey of a patient undergoing blood transfusions.
In this video clip, the panel discusses the RR6 model's ability to predict outcomes for patients treated with ruxolitinib, particularly identifying those who
